Earlier this week, Sarepta Therapeutics, Inc SRPT provided a safety update regarding Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the company is taking to strengthen the safety profile in non-ambulatory patients.These steps follow a second reported case of acute liver failure (ALF), resulting in death.William Blair says, “One key factor leading to investor hesitancy is the lack of clarity over how many additional non-am ...